An important therapy that has emerged for NSCLC is the immune checkpoint inhibitor, which would stop the interaction of the T cells with immune checkpoints, including CTLA-4 and PD-1/PDL-1 [115]. Here, CTLA4 is linked to non-small cell lung carcinoma.